{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T17:25:51Z","timestamp":1788801951628,"version":"build-2803163510"},"reference-count":109,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Sexual Medicine Reviews"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.sxmr.2019.02.004","type":"journal-article","created":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T20:39:30Z","timestamp":1554496770000},"page":"679-689","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Pathophysiology and Future Therapeutic Perspectives for Resolving Fibrosis in Peyronie\u2019s Disease"],"prefix":"10.1093","volume":"7","author":[{"given":"Uros","family":"Milenkovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus M.","family":"Ilg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selim","family":"Cellek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Albersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"10.1016\/j.sxmr.2019.02.004_bib1","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/andr.12058","article-title":"Therapeutic advances in the treatment of Peyronie\u2019s disease","volume":"3","author":"Yafi","year":"2015","journal-title":"Andrology"},{"key":"10.1016\/j.sxmr.2019.02.004_bib2","first-page":"1376","article-title":"The natural history of Peyronie\u2019s disease","volume":"144","author":"Gelbard","year":"1990","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib3","first-page":"2115","article-title":"An analysis of the natural history of Peyronie\u2019s disease","volume":"175","author":"Mulhall","year":"2006","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib4","first-page":"581","article-title":"Graft materials in Peyronie\u2019s disease surgery: A comprehensive review","volume":"4","author":"Kadioglu","year":"2007","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2019.02.004_bib5","first-page":"2350","article-title":"Subjective and objective analysis of the prevalence of Peyronie\u2019s disease in a population of men presenting for prostate cancer screening","volume":"171","author":"Mulhall","year":"2004","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib6","doi-asserted-by":"crossref","first-page":"280","DOI":"10.21037\/tau.2016.04.05","article-title":"Peyronie\u2019s disease: A literature review on epidemiology, genetics, pathophysiology, diagnosis and work-up","volume":"5","author":"Al-Thakafi","year":"2016","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib7","first-page":"544","article-title":"Contemporary review of grafting techniques for the surgical treatment of Peyronie\u2019s disease","volume":"5","author":"Hatzichristodoulou","year":"2017","journal-title":"Sex Med"},{"key":"10.1016\/j.sxmr.2019.02.004_bib8","first-page":"627","article-title":"Bother and distress associated with Peyronie\u2019s disease: Validation of the Peyronie\u2019s disease questionnaire","volume":"190","author":"Hellstrom","year":"2013","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib9","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.maturitas.2014.05.024","article-title":"Peyronie\u2019s disease: Review and recent advances","volume":"78","author":"Langston","year":"2014","journal-title":"Maturitas"},{"key":"10.1016\/j.sxmr.2019.02.004_bib10","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2012.05.040","article-title":"EAU guidelines on penile curvature","volume":"62","author":"Hatzimouratidis","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib11","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.eururo.2018.07.005","article-title":"Clinical efficacy of injection and mechanical therapy for Peyronie\u2019s disease: A systematic review of the literature","volume":"74","author":"Russo","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3109\/00365599109024539","article-title":"Regulation of the proliferation and biosynthetic activities of cultured human Peyronie\u2019s disease fibroblasts by interferons-alpha, -beta and -gamma","volume":"25","author":"Duncan","year":"1991","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib13","first-page":"2284","article-title":"An animal model of Peyronie\u2019s-like condition associated with an increase of transforming growth factor beta mrna and protein expression","volume":"158","author":"El-sakka","year":"1997","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib14","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1464-410x.1998.00529.x","article-title":"Histological and ultrastructural alterations in an animal model of Peyronie\u2019s disease","volume":"81","author":"El-Sakka","year":"1998","journal-title":"Br J Urol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib15","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S1089-8603(02)00124-6","article-title":"Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie\u2019s fibrotic plaque and in its rat model","volume":"7","author":"Vernet","year":"2002","journal-title":"Nitric Oxide Biol Chem"},{"key":"10.1016\/j.sxmr.2019.02.004_bib16","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/sj.ijir.3900874","article-title":"Peyronie\u2019s disease cell culture models: Phenotypic, genotypic and functional analyses","volume":"14","author":"Mulhall","year":"2002","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.sxmr.2019.02.004_bib17","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.niox.2003.12.002","article-title":"L-Arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie\u2019s fibrotic plaque and related fibroblast cultures","volume":"9","author":"Valente","year":"2003","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.sxmr.2019.02.004_bib18","first-page":"947","article-title":"Understanding the role of adenosine receptors in the myofibroblast transformation in Peyronie\u2019s disease","volume":"15","author":"Mateus","year":"2018","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2019.02.004_bib19","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.eururo.2018.10.014","article-title":"Antifibrotic synergy between phosphodiesterase type 5 inhibitors and selective oestrogen receptor modulators in Peyronie\u2019s disease models","volume":"75","author":"Ilg","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib20","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/bju.14638","article-title":"Simvastatin and the rho-kinase inhibitor Y-27632 prevent myofibroblast transformation in Peyronie\u2019s disease\u2013derived fibroblasts via inhibition of YAP\/TAZ nuclear translocation","volume":"123","author":"Milenkovic","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.sxmr.2019.02.004_bib21","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.exger.2004.06.022","article-title":"Molecular pathophysiology and gene therapy of aging-related erectile dysfunction","volume":"39","author":"Gonzalez-Cadavid","year":"2004","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib22","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1161\/hy09t1.096249","article-title":"Vascular remodeling in hypertension: Roles of apoptosis, inflammation, and fibrosis","volume":"38","author":"Intengan","year":"2001","journal-title":"Hypertens"},{"key":"10.1016\/j.sxmr.2019.02.004_bib23","first-page":"332","article-title":"Pharmacological intervention in renal fibrosis and vascular sclerosis","volume":"14","author":"Becker","year":"2001","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib24","first-page":"1234","article-title":"Peyronie\u2019s disease: A review","volume":"169","author":"Gholami","year":"2003","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib25","first-page":"285","article-title":"Proposal: Trauma as the cause of the Peyronie\u2019s lesion","volume":"157","author":"Devine","year":"1997","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib26","first-page":"324","article-title":"Exercise-induced rhabdomyolysis mechanisms and prevention: A literature review","volume":"5","author":"Kim","year":"2016","journal-title":"J\u00a0Sport Heal Sci"},{"key":"10.1016\/j.sxmr.2019.02.004_bib27","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/ncpuro0201","article-title":"Mechanisms of disease: New insights into the cellular and molecular pathology of Peyronie\u2019s disease","volume":"2","author":"Gonzalez-Cadavid","year":"2005","journal-title":"Nat Clin Pract Urol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib28","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nm.2807","article-title":"Mechanism of fibrosis: Therapeutic transplation for fibrotic disease","volume":"18","author":"Wynn","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.sxmr.2019.02.004_bib29","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1146\/annurev-pathol-020712-163930","article-title":"Host responses in tissue repair and fibrosis","volume":"8","author":"Duffield","year":"2013","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"10.1016\/j.sxmr.2019.02.004_bib30","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1056\/NEJMra1300575","article-title":"Fibrosis\u2014A common pathway to organ injury and failure","volume":"372","author":"Rockey","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.sxmr.2019.02.004_bib31","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/gutjnl-2014-306842","article-title":"Pathobiology of liver fibrosis: A translational success story","volume":"64","author":"Lee","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.sxmr.2019.02.004_bib32","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.jhep.2015.02.039","article-title":"Hepatic fibrosis: Concept to treatment","volume":"62","author":"Trautwein","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib33","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/hep.27332","article-title":"Hepatic inflammation and fibrosis: Functional links and key pathways","volume":"61","author":"Seki","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.sxmr.2019.02.004_bib34","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1172\/JCI60323","article-title":"Pulmonary fibrosis: patterns and perpetrators","volume":"122","author":"Noble","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.sxmr.2019.02.004_bib35","doi-asserted-by":"crossref","first-page":"221","DOI":"10.5858\/arpa.2015-0288-SA","article-title":"Update on pulmonary fibrosis: Not all fibrosis is created equally","volume":"140","author":"Smith","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.sxmr.2019.02.004_bib36","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/nrneph.2011.149","article-title":"Cellular and molecular mechanisms of renal fibrosis","volume":"7","author":"Liu","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib37","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.addr.2017.05.017","article-title":"Therapeutic pro-fibrogenic signaling pathways in fibroblasts","volume":"121","author":"Cannito","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.sxmr.2019.02.004_bib38","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1073\/pnas.1702750114","article-title":"Small molecule-mediated inhibition of myofibroblast transdifferentiation for the treatment of fibrosis","volume":"114","author":"Bollong","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.sxmr.2019.02.004_bib39","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0002-9440(10)63706-6","article-title":"An HSV-TK transgenic mouse model to evaluate elimination of fibroblasts for fibrosis therapy","volume":"163","author":"Tian","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib40","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.matbio.2018.01.019","article-title":"The big five in fibrosis: Macrophages, myofibroblasts, matrix, mechanics, and miscommunication","volume":"68\u201369","author":"Pakshir","year":"2018","journal-title":"Matrix Biol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib41","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/path.4104","article-title":"The myofibroblast matrix: Implications for tissue repair and fibrosis","volume":"229","author":"Klingberg","year":"2013","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib42","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.matbio.2015.05.006","article-title":"The extracellular matrix and transforming growth factor-\u03b21: Tale of a strained relationship","volume":"47","author":"Hinz","year":"2015","journal-title":"Matrix Biol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib43","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1524-475X.2008.00410.x","article-title":"Perspective article: Growth factors and cytokines in wound healing","volume":"16","author":"Barrientos","year":"2008","journal-title":"Wound Repair Regen"},{"key":"10.1016\/j.sxmr.2019.02.004_bib44","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41585-018-0109-7","article-title":"The mechanisms and potential of stem cell therapy for penile fibrosis","volume":"16","author":"Milenkovic","year":"2019","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib45","first-page":"1","article-title":"Macrophage polarization in chronic inflammatory diseases: Killers or builders?","volume":"2018","author":"Parisi","year":"2018","journal-title":"J\u00a0Immunol Res"},{"key":"10.1016\/j.sxmr.2019.02.004_bib46","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.immuni.2016.02.015","article-title":"Macrophages in tissue repair, regeneration, and fibrosis","volume":"44","author":"Wynn","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.sxmr.2019.02.004_bib47","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nature12034","article-title":"Macrophage biology in development, homeostasis and disease","volume":"496","author":"Wynn","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.sxmr.2019.02.004_bib48","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.2353\/ajpath.2007.070112","article-title":"The myofibroblast: one function, multiple origins","volume":"170","author":"Hinz","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib49","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.biocel.2006.11.005","article-title":"Fibroblasts and myofibroblasts: Their source, function and role in disease","volume":"39","author":"McAnulty","year":"2007","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib50","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.mam.2007.09.002","article-title":"Myofibroblast-like cells and liver fibrogenesis: Emerging concepts in a rapidly moving scenario","volume":"29","author":"Parola","year":"2008","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.sxmr.2019.02.004_bib51","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.ajpath.2012.02.004","article-title":"Recent developments in myofibroblast biology","volume":"180","author":"Hinz","year":"2012","journal-title":"Am J Pathol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib52","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.abb.2014.02.015","article-title":"Cellular and molecular mechanisms in liver fibrogenesis","volume":"548","author":"Novo","year":"2014","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.sxmr.2019.02.004_bib53","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jhep.2008.12.011","article-title":"Angiogenesis in liver disease","volume":"50","author":"Fern\u00e1ndez","year":"2009","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib54","first-page":"303","article-title":"Experimental models of Peyronie\u2019s disease. Implications for new therapies","volume":"6","author":"Gonzalez-Cadavid","year":"2009","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2019.02.004_bib55","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/path.2277","article-title":"Cellular and molecular mechanisms of fibrosis","volume":"214","author":"Wynn","year":"2008","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib56","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.2353\/ajpath.2007.060887","article-title":"Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells","volume":"170","author":"Novo","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib57","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/sj.ijir.3900311","article-title":"Engineering analysis of penile hemodynamic and structural-dynamic relationships: Part II\u2014Clinical implications of penile buckling","volume":"10","author":"Udelson","year":"1998","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.sxmr.2019.02.004_bib58","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/sj.ijir.3900443","article-title":"Axial penile buckling forces vs Rigiscan radial rigidity as a function of intracavernosal pressure: Why Rigiscan does not predict functional erections in individual patients","volume":"11","author":"Udelson","year":"1999","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.sxmr.2019.02.004_bib59","first-page":"1844","article-title":"\u03b11A-Adrenergic receptor antagonism improves erectile and cavernosal responses in rats with cavernous nerve injury and enhances neurogenic responses in human corpus cavernosum from patients with erectile dysfunction secondary to radical prostatectomy","volume":"13","author":"Mart\u00ednez-Salamanca","year":"2016","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2019.02.004_bib60","first-page":"186","article-title":"Trauma as the Cause of Peyronie\u2019s Disease: Penile Fracture as a Model of Trauma","volume":"172","author":"Zargooshi","year":"2004","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib61","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1097\/01.ASN.0000098686.72971.DB","article-title":"Hepatocyte growth factor modulates matrix metalloproteinases and plasminogen activator\/plasmin proteolytic pathways in progressive renal interstitial fibrosis","volume":"14","author":"Gong","year":"2003","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib62","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.urology.2005.01.010","article-title":"Peyronie\u2019s disease associated with increase in plasminogen activator inhibitor in fibrotic plaque","volume":"65","author":"Davila","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.sxmr.2019.02.004_bib63","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/S0006-291X(02)00765-9","article-title":"Upregulation of monocyte chemoattractant protein 1 and effects of transforming growth factor-b 1 in Peyronie\u2019s disease","volume":"295","author":"Lin","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.sxmr.2019.02.004_bib64","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/35043051","article-title":"How cells read TGF-beta signals","volume":"1","author":"Massagu\u00e9","year":"2000","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib65","doi-asserted-by":"crossref","first-page":"487","DOI":"10.4103\/1008-682X.142130","article-title":"Effect of SMAD7 gene overexpression on TGF-\u03b21-induced profibrotic responses in fibroblasts derived from Peyronie\u2032s plaque","volume":"17","author":"Choi","year":"2015","journal-title":"Asian J Androl"},{"key":"10.1016\/j.sxmr.2019.02.004_bib66","doi-asserted-by":"crossref","first-page":"C2","DOI":"10.1152\/ajpcell.00060.2014","article-title":"Cellular mechanisms of tissue fibrosis. 8. Current and future drug targets in fibrosis: focus on Rho GTPase-regulated gene transcription","volume":"307","author":"Tsou","year":"2014","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib67","series-title":"Transcriptome-wide analysis of Peyronie\u2019s disease plaques using RNA sequencing uncovers targetable signalling pathways for medical therapy","author":"Milenkovic","year":"2018"},{"key":"10.1016\/j.sxmr.2019.02.004_bib68","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1006\/niox.2001.0421","article-title":"Antifibrotic role of inducible nitric oxide synthase","volume":"6","author":"Ferrini","year":"2002","journal-title":"Nitric Oxide"},{"issue":"Suppl. 5","key":"10.1016\/j.sxmr.2019.02.004_bib69","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1038\/sj.ijir.3901082","article-title":"Expanding the paradigm for plaque development in Peyronie\u2019s disease","volume":"15","author":"Mulhall","year":"2003","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.sxmr.2019.02.004_bib70","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.cardiores.2003.12.006","article-title":"Aging-related induction of inducible nitric oxide synthase is vasculo-protective to the arterial media","volume":"61","author":"Ferrini","year":"2004","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.sxmr.2019.02.004_bib71","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1095\/biolreprod64.3.974","article-title":"Aging-related expression of inducible nitric oxide synthase and markers of tissue damage in the rat penis","volume":"64","author":"Ferrini","year":"2001","journal-title":"Biol Reprod"},{"key":"10.1016\/j.sxmr.2019.02.004_bib72","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.eururo.2012.09.034","article-title":"Intratunical injection of human adipose tissue\u2013derived stem cells prevents fibrosis and is associated with improved erectile function in a rat model of Peyronie\u2019s disease","volume":"63","author":"Castiglione","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib73","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.2047-2927.2013.00181.x","article-title":"Adipose tissue\u2013derived stem cell therapy for prevention and treatment of erectile dysfunction in a rat model of Peyronie\u2019s disease","volume":"2","author":"Gokce","year":"2014","journal-title":"Andrology"},{"key":"10.1016\/j.sxmr.2019.02.004_bib74","first-page":"1533","article-title":"Intratunical injection of genetically modified adipose tissue-derived stem cells with human interferon \u03b1-2b for treatment of erectile dysfunction in a rat model of tunica albugineal fibrosis","volume":"12","author":"Gokce","year":"2015","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2019.02.004_bib75","first-page":"5149","article-title":"Inhibition of penile tunica albuginea myofibroblasts activity by adipose-derived stem cells","volume":"14","author":"Jiang","year":"2017","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.sxmr.2019.02.004_bib76","author":"Castiglione"},{"key":"10.1016\/j.sxmr.2019.02.004_bib77","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.esxm.2018.09.003","article-title":"Intratunical injection of human adipose tissue\u2013derived stem cells restores collagen III\/I ratio in a rat model of chronic Peyronie\u2019s disease","volume":"7","author":"Castiglione","year":"2019","journal-title":"Sex Med"},{"key":"10.1016\/j.sxmr.2019.02.004_bib78","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.sxmr.2015.10.002","article-title":"The genetic basis of Peyronie disease: A review","volume":"4","author":"Herati","year":"2016","journal-title":"Sex Med Rev"},{"key":"10.1016\/j.sxmr.2019.02.004_bib79","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ajmg.1320120213","article-title":"Peyronie\u2019s disease: A newly recognized autosomal-dominant trait","volume":"12","author":"Bias","year":"1982","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.sxmr.2019.02.004_bib80","first-page":"34","article-title":"The association of histocompatibility antigens of the B7 cross-reacting group with Peyronie\u2019s disease","volume":"122","author":"Willscher","year":"1979","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib81","first-page":"1223","article-title":"Non-association of Peyronie\u2019s disease with HLA B7 cross-reactive antigens","volume":"127","author":"Leffell","year":"1982","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib82","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/0090-4295(84)90068-2","article-title":"HLA-A and B antigens in patients with Peyronie disease","volume":"23","author":"Deguchi","year":"1984","journal-title":"Urology"},{"key":"10.1016\/j.sxmr.2019.02.004_bib83","first-page":"369","article-title":"Prospective analysis of single nucleotide polymorphisms of the transforming growth factor beta-1 gene in Peyronie\u2019s disease","volume":"169","author":"Hauck","year":"2003","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib84","first-page":"672","article-title":"Chromosome abnormalities in Peyronie\u2019s disease","volume":"137","author":"Somers","year":"1987","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib85","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/sj.ijir.3901170","article-title":"Chromosomal instability is demonstrated by fibroblasts derived from the tunica of men with Peyronie\u2019s disease","volume":"16","author":"Mulhall","year":"2004","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.sxmr.2019.02.004_bib86","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1097\/00007890-199810270-00009","article-title":"Genotypic variation in the transforming growth factor-beta1 gene: Association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation","volume":"66","author":"Awad","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.sxmr.2019.02.004_bib87","first-page":"1430","article-title":"WNT2 locus is involved in genetic susceptibility of Peyronie\u2019s disease","volume":"9","author":"Dolmans","year":"2012","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2019.02.004_bib88","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1101029","article-title":"Wnt signaling and Dupuytren\u2019s disease","volume":"365","author":"Dolmans","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.sxmr.2019.02.004_bib89","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0090-4295(01)01578-3","article-title":"Gene expression profiles in the Peyronie\u2019s disease plaque","volume":"59","author":"Magee","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.sxmr.2019.02.004_bib90","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1006\/excr.2000.4930","article-title":"Modulation of endogenous smad expression in normal skin fibroblasts by transforming growth factor-\u03b2","volume":"258","author":"Mori","year":"2000","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.sxmr.2019.02.004_bib91","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/S1097-2765(00)00134-9","article-title":"Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation","volume":"6","author":"Kavsak","year":"2000","journal-title":"Mol Cell"},{"key":"10.1016\/j.sxmr.2019.02.004_bib92","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrd3480","article-title":"How were new medicines discovered?","volume":"10","author":"Swinney","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.sxmr.2019.02.004_bib93","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/nrd2199","article-title":"How many drug targets are there?","volume":"5","author":"Overington","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.sxmr.2019.02.004_bib94","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.2174\/156802606778194226","article-title":"Rethinking target discovery in polygenic diseases","volume":"6","author":"Flordellis","year":"2006","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.sxmr.2019.02.004_bib95","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nrd4592","article-title":"Dissecting fibrosis: Therapeutic insights from the small-molecule toolbox","volume":"14","author":"Nanthakumar","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.sxmr.2019.02.004_bib96","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/nrd4366","article-title":"Phenotypic screening in cancer drug discovery\u2014Past, present and future","volume":"13","author":"Moffat","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.sxmr.2019.02.004_bib97","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrurol.2010.24","article-title":"Treatment of Peyronie\u2019s disease with PDE5 inhibitors: An antifibrotic strategy","volume":"7","author":"Gonzalez-Cadavid","year":"2010","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib98","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1681\/ASN.2011010046","article-title":"Antifibrotic effect of tamoxifen in a model of progressive renal disease","volume":"23","author":"Dell\u00ea","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib99","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.eururo.2006.02.059","article-title":"A\u00a0critical analysis of nonsurgical treatment of Peyronie\u2019s disease","volume":"49","author":"Hauck","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib100","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.euf.2018.08.026","article-title":"Surgical management of Peyronie\u2019s disease","volume":"4","author":"Tsambarlis","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.sxmr.2019.02.004_bib101","first-page":"745","article-title":"Peyronie\u2019s disease: AUA Guideline","volume":"194","author":"Nehra","year":"2015","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib102","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1365-2605.2011.01226.x","article-title":"Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie\u2019s disease and erectile dysfunction: Results from a prospective randomized trial","volume":"35","author":"Palmieri","year":"2012","journal-title":"Int J Androl"},{"key":"10.1016\/j.sxmr.2019.02.004_bib103","doi-asserted-by":"crossref","first-page":"345","DOI":"10.4103\/0974-7796.152048","article-title":"Tadalafil once daily and intralesional verapamil injection: A new therapeutic direction in Peyronie\u2019s disease","volume":"7","author":"Dell\u2019Atti","year":"2015","journal-title":"Urol Ann"},{"key":"10.1016\/j.sxmr.2019.02.004_bib104","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11845-013-1036-5","article-title":"Effects of sildenafil treatment on patients with Peyronie\u2019s disease and erectile dysfunction","volume":"183","author":"Ozturk","year":"2014","journal-title":"Irish J Med Sci"},{"key":"10.1016\/j.sxmr.2019.02.004_bib105","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1464-410X.1992.tb15836.x","article-title":"The treatment of Peyronie\u2019s disease with Tamoxifen","author":"Ralph","year":"1992","journal-title":"Br J Urol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib106","first-page":"S57","article-title":"The use of tamoxifen in the treatment of Peyronie\u2019s disease","volume":"10","author":"Apaydin","year":"1998","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.sxmr.2019.02.004_bib107","first-page":"2003","article-title":"Tamoxifen versus placebo in the treatment of Peyronie\u2019s disease","volume":"162","author":"Teloken","year":"1999","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2019.02.004_bib108","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.bbadis.2013.01.018","article-title":"Strategies for biomarker discovery in fibrotic disease","volume":"1832","author":"Marshall","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.sxmr.2019.02.004_bib109","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","article-title":"RESOURCE A Next Generation Connectivity Map: L1000 platform and the first 1,000,000 profiles","volume":"171","author":"Subramanian","year":"2017","journal-title":"Cell"}],"container-title":["Sexual Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2050052119300113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2050052119300113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T09:00:43Z","timestamp":1694768443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2050052119300113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":109,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S2050052119300113"],"URL":"https:\/\/doi.org\/10.1016\/j.sxmr.2019.02.004","relation":{},"ISSN":["2050-0521"],"issn-type":[{"value":"2050-0521","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathophysiology and Future Therapeutic Perspectives for Resolving Fibrosis in Peyronie\u2019s Disease","name":"articletitle","label":"Article Title"},{"value":"Sexual Medicine Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sxmr.2019.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}